[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336401-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336401-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","biomarkers-in-thyroid-cancer-emerging-opportunities-from-non-coding-rnas-and-mitochondrial-space","Biomarkers in Thyroid Cancer - Emerging Opportunities from Non-Coding RNAs and Mitochondrial Space","","Thyroid cancer diagnosis relies mainly on imaging and cytological analyses, but molecular marker quantification is used when results are uncertain. This strategy supports surgical decision-making, helps estimate aggressiveness, and enables monitoring of treatment response. Although commercial molecular tests exist, cost constraints and inter-test variability limit routine adoption. The review surveys preoperative testing approaches and emerging molecular markers, emphasizing micro RNAs, long non-coding RNAs, and mitochondrial signatures, including mtDNA genes and circulating cell-free mtDNA.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/biomarkers-in-thyroid-cancer-emerging-opportunities-from-non-coding-rnas-and-mitochondrial-space/336401/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/biomarkers-in-thyroid-cancer-emerging-opportunities-from-non-coding-rnas-and-mitochondrial-space/336401.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are molecular markers used in thyroid cancer diagnosis?","Question",{"text":63,"@type":64},"When imaging and cytology cannot provide a clear diagnosis, quantifying molecular markers after cytological examination helps improve diagnostic certainty, guide surgical decisions, and support risk assessment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limits the widespread use of commercial molecular tests?",{"text":68,"@type":64},"Cost constraints and variability between tests have hindered their routine adoption in clinical practice.",{"name":70,"@type":61,"acceptedAnswer":71},"Which molecular marker categories does the review focus on?",{"text":72,"@type":64},"The review highlights micro RNAs, long non-coding RNAs, and mitochondrial signatures, including mtDNA genes and circulating cell-free mtDNA.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336401,1790563638,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Review  \nBiomarkers in Thyroid Cancer: Emerging Opportunities from Non-Coding RNAs and Mitochondrial Space  \nPatricio Cabané 1,2,3, Claudio Correa 1,2, Ignacio Bode 4, Rodrigo Aguilar 4, * and Alvaro A. Elorza 4, *  \nCitation: Cabané, P.; Correa, C.; Bode, I.; Aguilar, R.; Elorza, A.A.  \nBiomarkers in Thyroid Cancer: Emerging Opportunities from Non-Coding RNAs and Mitochondrial Space. Int. J. Mol. Sci. 2024, 25, 6719. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms25126719](10.3390/ijms25126719)  \nAcademic Editors: Cristina Peña, Rosita Curcio, Vincenza Dolce and Graziantonio Lauria  \nReceived: 20 April 2024  \nRevised: 1 June 2024  \nAccepted: 14 June 2024  \nPublished: 18 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Head and Neck Surgery, Clinica INDISA, Santiago 7520440, Chile;  \n[patricio.cabane@indisa.cl](patricio.cabane@indisa.cl) (P.C.); [c.correallanos@uandresbello.edu](c.correallanos@uandresbello.edu) (C.C.)  \n2 Faculty of Medicine, Universidad Andres Bello, Santiago 8370071, Chile  \n3 Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile  \n4 Institute of Biomedical Sciences, Faculty of Medicine and Faculty of Life Sciences, Universidad Andres Bello, Santiago 8370071, Chile; [ignacio.bode@gmail.com](ignacio.bode@gmail.com)  \n* Correspondence: [rodrigo.aguilar@unab.cl](rodrigo.aguilar@unab.cl) (R.A.); [alvaro.elorza@unab.cl](alvaro.elorza@unab.cl) (A.A.E.)  \nAbstract: Thyroid cancer diagnosis primarily relies on imaging techniques and cytological analyses. In cases where the diagnosis is uncertain, the quantification of molecular markers has been incorporated after cytological examination. This approach helps physicians to make surgical decisions, estimate cancer aggressiveness, and monitor the response to treatments. Despite the availability of commercial molecular tests, their widespread use has been hindered in our experience due to cost constraints and variability between them. Thus, numerous groups are currently evaluating new molecular markers that ultimately will lead to improved diagnostic certainty, as well as better classification of prognosis and recurrence. In this review, we start reviewing the current preoperative testing methodologies, followed by a comprehensive review of emerging molecular markers. We focus on micro RNAs, long non-coding RNAs, and mitochondrial (mt) signatures, including mtDNA genes and circulating cell-free mtDNA. We envision that a robust set of molecular markers will complement the national and international clinical guides for proper assessment of the disease.  \nKeywords: thyroid cancer; diagnosis; molecular markers; non-coding RNAs; mitochondria  \n1. Introduction  \nThyroid cancer accounts for 1 to 4% of all malignancies worldwide. Its incidence has increased over the years, from 1.5% before 1996 to 6.8% after 1996, with an increase of three times per decade [1](for a definition of epidemiological terms, see Table 1) . In Chile, the estimated number of new cases per year is 1300 [2] . This increase in incidence has been attributed to a higher diagnosis rate, mainly due to the implementation of imaging techniques (diagnosis achieved in 50% of cases), as well as genetic and environmental factors, such as obesity and the increase in iodine consumption [1] . Histologically, thyroid cancer develops in two cell types, with more than 90% derived from follicular cells (epithelial, responsible for the uptake of iodine and production of thyroid hormones), and 3–5% derived from parafollicular cells (associated with synthesis and production of calcitonin) . According to the WHO 2022 ","cbCaipuIczvCD1h4","https://ap.wps.com/l/cbCaipuIczvCD1h4","pdf",419148,"English","# Abstract\n# Introduction\n## Diagnosis and Uncertainty in Thyroid Cancer\n# Molecular Markers and Emerging Opportunities\n## Non-Coding RNAs\n## Mitochondrial (mt) Signatures","[{\"question\":\"Why are molecular markers used in thyroid cancer diagnosis?\",\"answer\":\"When imaging and cytology cannot provide a clear diagnosis, quantifying molecular markers after cytological examination helps improve diagnostic certainty, guide surgical decisions, and support risk assessment.\"},{\"question\":\"What limits the widespread use of commercial molecular tests?\",\"answer\":\"Cost constraints and variability between tests have hindered their routine adoption in clinical practice.\"},{\"question\":\"Which molecular marker categories does the review focus on?\",\"answer\":\"The review highlights micro RNAs, long non-coding RNAs, and mitochondrial signatures, including mtDNA genes and circulating cell-free mtDNA.\"}]","Biomarkers in Thyroid Cancer - Emerging Opportunities from Non-Coding RNAs and Mitochondrial Space | PDF",1790014882,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d4c48214fcd4273e98e0508de9b7021.webp",983,1390,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5ae9f5913f4c8ccdcc262771d1c9576.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43de60ac8b78518d85e2bda2fb8f63de.webp",981,1387,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b40b01036518d319619100dcec17b4cd.webp",980,1385]